Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 57

Cited In for PubMed (Select 19901119)

1.

SVSI: Fast and Powerful Set-Valued System Identification Approach to Identifying Rare Variants in Sequencing Studies for Ordered Categorical Traits.

Bi W, Kang G, Zhao Y, Cui Y, Yan S, Li Y, Cheng C, Pounds SB, Borowitz MJ, Relling MV, Yang JJ, Liu Z, Pui CH, Hunger SP, Hartford CM, Leung W, Zhang JF.

Ann Hum Genet. 2015 Jul;79(4):294-309. doi: 10.1111/ahg.12117. Epub 2015 May 11.

PMID:
25959545
2.

The physiological role of drug transporters.

Liang Y, Li S, Chen L.

Protein Cell. 2015 May;6(5):334-50. doi: 10.1007/s13238-015-0148-2. Epub 2015 Mar 24.

3.

Role of Organic Anion-Transporting Polypeptides (OATPs) in Cancer Therapy.

Thakkar N, Lockhart AC, Lee W.

AAPS J. 2015 May;17(3):535-45. doi: 10.1208/s12248-015-9740-x. Epub 2015 Mar 4.

PMID:
25735612
4.

Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy.

Zhang X, Pu Z, Ge J, Shen J, Yuan X, Xie H.

Med Sci Monit. 2015 Feb 21;21:563-9. doi: 10.12659/MSM.893473.

5.

Genome-wide association studies in Africans and African Americans: expanding the framework of the genomics of human traits and disease.

Peprah E, Xu H, Tekola-Ayele F, Royal CD.

Public Health Genomics. 2015;18(1):40-51. Epub 2014 Nov 26.

6.

Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections.

Wright KD, Panetta JC, Onar-Thomas A, Reddick WE, Patay Z, Qaddoumi I, Broniscer A, Robinson G, Boop FA, Klimo P Jr, Ward D, Gajjar A, Stewart CF.

Cancer Chemother Pharmacol. 2015 Jan;75(1):27-35. doi: 10.1007/s00280-014-2614-6. Epub 2014 Oct 24.

PMID:
25342291
7.

A comprehensive evaluation of collapsing methods using simulated and real data: excellent annotation of functionality and large sample sizes required.

Dering C, König IR, Ramsey LB, Relling MV, Yang W, Ziegler A.

Front Genet. 2014 Sep 15;5:323. doi: 10.3389/fgene.2014.00323. eCollection 2014.

8.

Implementation and utilization of genetic testing in personalized medicine.

Abul-Husn NS, Owusu Obeng A, Sanderson SC, Gottesman O, Scott SA.

Pharmgenomics Pers Med. 2014 Aug 13;7:227-40. doi: 10.2147/PGPM.S48887. eCollection 2014. Review.

9.

Multi-agent chemotherapy overcomes glucocorticoid resistance conferred by a BIM deletion polymorphism in pediatric acute lymphoblastic leukemia.

Soh SX, Lim JY, Huang JW, Jiang N, Yeoh AE, Ong ST.

PLoS One. 2014 Aug 4;9(8):e103435. doi: 10.1371/journal.pone.0103435. eCollection 2014.

10.

Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma.

Goricar K, Kovac V, Dolzan V.

Radiol Oncol. 2014 Apr 25;48(2):163-72. doi: 10.2478/raon-2013-0086. eCollection 2014 Jun.

11.

Pharmacogenomics in oncology care.

Filipski KK, Mechanic LE, Long R, Freedman AN.

Front Genet. 2014 Apr 8;5:73. doi: 10.3389/fgene.2014.00073. eCollection 2014. Review.

12.

Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia.

López-López E, Gutiérrez-Camino Á, Piñán MÁ, Sánchez-Toledo J, Uriz JJ, Ballesteros J, García-Miguel P, Navajas A, García-Orad Á.

PLoS One. 2014 Mar 10;9(3):e91261. doi: 10.1371/journal.pone.0091261. eCollection 2014.

13.

Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia.

Bhojwani D, Sabin ND, Pei D, Yang JJ, Khan RB, Panetta JC, Krull KR, Inaba H, Rubnitz JE, Metzger ML, Howard SC, Ribeiro RC, Cheng C, Reddick WE, Jeha S, Sandlund JT, Evans WE, Pui CH, Relling MV.

J Clin Oncol. 2014 Mar 20;32(9):949-59. doi: 10.1200/JCO.2013.53.0808. Epub 2014 Feb 18.

14.

The intestinal absorption of folates.

Visentin M, Diop-Bove N, Zhao R, Goldman ID.

Annu Rev Physiol. 2014;76:251-74. doi: 10.1146/annurev-physiol-020911-153251. Review.

15.

Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.

Benz-de Bretagne I, Zahr N, Le Gouge A, Hulot JS, Houillier C, Hoang-Xuan K, Gyan E, Lissandre S, Choquet S, Le Guellec C.

Br J Clin Pharmacol. 2014 Aug;78(2):329-42. doi: 10.1111/bcp.12326.

PMID:
24433481
16.

Uptake carriers and oncology drug safety.

Sprowl JA, Sparreboom A.

Drug Metab Dispos. 2014 Apr;42(4):611-22. doi: 10.1124/dmd.113.055806. Epub 2013 Dec 30. Review.

17.

Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics.

Murakami T, Mori N.

Pharmaceuticals (Basel). 2012 Aug 10;5(8):802-36. doi: 10.3390/ph5080802.

18.

A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor.

Lubieniecka JM, Graham J, Heffner D, Mottus R, Reid R, Hogge D, Grigliatti TA, Riggs WK.

Front Genet. 2013 Nov 11;4:231. doi: 10.3389/fgene.2013.00231. eCollection 2013.

19.

Promise of pharmacogenomics for drug discovery, treatment and prevention of Parkinson's disease. A perspective.

Payami H, Factor SA.

Neurotherapeutics. 2014 Jan;11(1):111-6. doi: 10.1007/s13311-013-0237-y. Review.

20.

SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer.

Huang L, Zhang T, Xie C, Liao X, Yu Q, Feng J, Ma H, Dai J, Li M, Chen J, Zang A, Wang Q, Ge S, Qin K, Cai J, Yuan X.

PLoS One. 2013 Oct 15;8(10):e77223. doi: 10.1371/journal.pone.0077223. eCollection 2013.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk